Taschner C A, Vedantham S, de Vries J, Biondi A, Boogaarts J, Sakai N, Lylyk P, Szikora I, Meckel S, Urbach H, Kan P, Siekmann R, Bernardy J, Gounis M J, Wakhloo A K
From the Department of Neuroradiology (C.A.T., S.M., H.U., J.B.), Medical Centre-University of Freiburg, Freiburg, Germany
Department of Radiology (S.V.).
AJNR Am J Neuroradiol. 2017 Mar;38(3):582-589. doi: 10.3174/ajnr.A5029. Epub 2016 Dec 22.
Flow diverters for the treatment of posterior circulation aneurysms remain controversial. We aimed to identify factors contributing to outcome measures in patients treated with the Surpass flow diverter for aneurysms in this location.
We conducted an observational study of 53 patients who underwent flow-diverter treatment for posterior circulation aneurysms at 15 centers. Key outcome measures were mortality, complete aneurysm occlusion, and modified Rankin Scale score at follow-up.
At follow-up (median, 11.3 months; interquartile range, 5.9-12.7 months), 9 patients had died, resulting in an all-cause mortality rate of 17.3% (95% CI, 7%-27.6%); 7 deaths (14%) were directly related to the procedure and none occurred in patients with a baseline mRS score of zero. After adjusting for covariates, a baseline mRS of 3-5 was more significantly ( = .003) associated with a higher hazard ratio for death than a baseline mRS of 0-2 (hazard ratio, 17.11; 95% CI, 2.69-109.02). After adjusting for follow-up duration, a 1-point increase in the baseline mRS was significantly ( < .001) associated with higher values of mRS at follow-up (odds ratio, 2.93; 95% CI, 1.79-4.79). Follow-up angiography in 44 patients (median, 11.3 months; interquartile range, 5.9-12.7 months) showed complete aneurysm occlusion in 29 (66%; 95% CI, 50.1%-79.5%).
Clinical results of flow-diverter treatment of posterior circulation aneurysms depend very much on patient selection. In this study, poorer outcomes were related to the treatment of aneurysms in patients with higher baseline mRS scores. Angiographic results showed a high occlusion rate for this subset of complex aneurysms.
用于治疗后循环动脉瘤的血流导向装置仍存在争议。我们旨在确定在使用Surpass血流导向装置治疗该部位动脉瘤的患者中,影响预后指标的因素。
我们对15个中心接受后循环动脉瘤血流导向治疗的53例患者进行了一项观察性研究。关键预后指标为死亡率、动脉瘤完全闭塞情况以及随访时的改良Rankin量表评分。
随访时(中位数为11.3个月;四分位间距为5.9 - 12.7个月),9例患者死亡,全因死亡率为17.3%(95%CI,7% - 27.6%);7例死亡(14%)与手术直接相关,且基线改良Rankin量表评分为零的患者无死亡发生。在对协变量进行调整后,基线改良Rankin量表评分为3 - 5分与死亡风险比高于基线改良Rankin量表评分为0 - 2分相比,差异更显著(P = 0.003)(风险比,17.11;95%CI,2.69 - 109.02)。在对随访时间进行调整后,基线改良Rankin量表评分每增加1分与随访时改良Rankin量表评分更高显著相关(P < 0.001)(优势比,2.93;95%CI,1.79 - 4.79)。44例患者(中位数为11.3个月;四分位间距为5.9 - 12.7个月)的随访血管造影显示,29例(66%;95%CI,50.1% - 79.5%)动脉瘤完全闭塞。
后循环动脉瘤血流导向治疗的临床结果很大程度上取决于患者的选择。在本研究中,预后较差与基线改良Rankin量表评分较高的患者的动脉瘤治疗有关。血管造影结果显示该复杂动脉瘤亚组的闭塞率较高。